Pharma Phriday (May 1, 2026): A week of bold dealmaking and standout clinical milestones, including a landmark gene-editing readout. AI momentum continued with another high-value partnership. Regulators delivered unusually wide-ranging decisions, including a serious alleged trial-fraud case. Major acquisitions reshaped rare disease, oncology and neuroscience, alongside UK reform and early sales data for a new obesity drug.

This week’s Pharma Phriday (April 24, 2026) covers major AI platform launches and enterprise partnerships, showing AI is expanding beyond drug discovery into wider roles. Clinical trials in respiratory, haematology, and neurology had mixed results, while regulators approved products in vaccines, immunology, oncology, and infectious disease. The industry saw notable consolidation with several multi-billion dollar acquisitions in gene therapy, regenerative medicine, and biosimi

Pharma Phriday (April 3, 2026): Clinical advances span sleep disorders, respiratory disease, dermatology, cardiovascular risk, and autoimmune conditions. Regulatory highlights cover diabetes, haematological malignancies, and biosimilars. Commercially, M&A activity dominated, alongside AI-driven R&D partnerships.

Pharma Phriday (March 27, 2026): Advances in obesity, diabetes, and rare neuromuscular disease; new approvals in lymphoma, paediatrics, ophthalmology, and obesity; major acquisitions in haematology and autoimmune; and licensing deals for T-cell engagers, oncology, subQ delivery, and AI.

In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.

This week we've had Eyes On Commercial Development and the FDA. Several companies have announced partnerships / acquisitions to further boost their pipelines and strengthen their competitive advantage.

We've been keeping Eyes On the updates coming out along with the 2Q25 Results. Lots of news on strategic Plans, M&A, Clinical Data, and more.

For ten titans of industry in 2025, the U.S. patent runway is coming to a close.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

2024 is off to a busy start with M&A activities highlighted at the JP Morgan Healthcare Conference, plus another Genetic Medicines approval.